HLA-G1 and HLA-G5 isoforms have an additive effect on NK cytolysis

Human Immunology

Volumn 75, Issue 2, 2014, Pages 182-189

  Zhang, Wei Qun ^a   Xu, Dan Ping ^b   Liu, Di ^b   Li, Ying Ying ^b   Ruan, Yan Yun ^b   Lin, Aifen ^b   Yan, Wei Hua ^b  

^a Lin'an People's Hospital   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HLA G ANTIGEN; HLA G1 ANTIGEN; HLA G5 ANTIGEN; ISOPROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BIOLOGICAL ACTIVITY; CELL ACTIVITY; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; NATURAL KILLER CELL; PRIORITY JOURNAL; TARGET CELL; CELL SEPARATION; CYTOTOXICITY; FLOW CYTOMETRY; GENETICS; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; K562 CELL LINE; METABOLISM; TRANSGENE;

CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HLA-G ANTIGENS; HUMANS; IMMUNE EVASION; IMMUNE TOLERANCE; K562 CELLS; KILLER CELLS, NATURAL; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN ISOFORMS; TRANSGENES;

EID: 84892367088     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.11.001     Document Type: Article

References (35)

1. González A., Rebmann V., LeMaoult J., Horn P.A., Carosella E.D., Alegre E. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 2012, 49:63-84.
2. Yan W.H. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets 2011, 11:76-89.
3. Yan W.H. Human leukocyte antigen-G in cancer: are they clinically relevant?. Cancer Lett 2011, 311:123-130.
4. Yan W.H., Lin A. HLA-G: biology, functions and roles in disease. Major histocompatibility complex: biology, functions and roles in disease 2012, Nova Science Publishers, Inc, New York, p. 79-117. N.V. Semiletova (Ed.).
5. Dahl M., Hviid T.V. Human leucocyte antigen class Ib molecules in pregnancy success and early pregnancy loss. Hum Reprod Update 2012, 18:92-109.
6. Rajagopalan S. Endosomal signaling and a novel pathway defined by the natural killer receptor KIR2DL4 (CD158d). Traffic 2010, 11:1381-1390.
7. Rajagopalan S., Moyle M.W., Joosten I., Long E.O. DNA-PKcs controls an endosomal signaling pathway for a proinflammatory response by natural killer cells. Sci Signal 2010, 3:ra14.
8. Agaugué S., Carosella E.D., Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011, 117:7021-7031.
9. Lesport E., Baudhuin J., Sousa S., LeMaoult J., Zamborlini A., Rouas-Freiss N., et al. Inhibition of human gamma delta T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci 2011, 68:3385-3399.
10. Lin A., Yan W.H., Xu H.H., Gan M.F., Cai J.F., Zhu M., et al. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol 2007, 18:1804-1809.
11. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004, 294:15-22.
12. Aktas E., Kucuksezer U.C., Bilgic S., Erten G., Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009, 254:149-154.
13. Lin A., Chen H.X., Zhu C.C., Zhang X., Xu H.H., Zhang J.G., et al. Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 2010, 14:2162-2171.
14. Thielens A., Vivier E., Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 2012, 24:239-245.
15. Park Y., Lim H.S., Kim Y.S., Hong D.J., Kim H.S. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. Tissue Antigens 2012, 79:97-103.
16. Han Q., Li N., Zhu Q., Li Z., Zhang G., Chen J., et al. Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection. Clin Exp Med 2012, 10.1007/s10238-012-0214-5.
17. de Oliveira Crispim J.C., Silva T.G., Souto F.J., Souza F.F., Bassi C.L., et al. Upregulation of soluble and membrane-bound human leukocyte antigen G expression is primarily observed in the milder histopathological stages of chronic hepatitis C virus infection. Hum Immunol 2012, 73:258-262.
18. Thibodeau V., Lajoie J., Labbé A.C., Zannou M.D., Fowke K.R., Alary M., et al. High level of soluble HLA-G in the female genital tract of Beninese commercial sex workers is associated with HIV-1 infection. PLoS One 2011, 6:e25185.
19. Baudhuin J., Migraine J., Faivre V., Loumagne L., Lukaszewicz A.C., Payen D., et al. Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions. Proc Natl Acad Sci USA 2013, 110:17957-17962.
20. Monneret G., Voirin N., Krawice-Radanne I., Bohé J., Lepape A., Rouas-Freiss N., et al. Soluble human leukocyte antigen-G5 in septic shock: marked and persisting elevation as a predictor of survival. Crit Care Med 2007, 35:1942-1947.
21. Lin A., Zhang X., Xu H.H., Xu D.P., Ruan Y.Y., Yan W.H. HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer. Int J Cancer 2012, 131:150-157.
22. Lin A., Xu H.H., Xu D.P., Zhang X., Wang Q., Yan W.H. Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression. Hum Immunol 2013, 74:439-446.
23. Guo Y., Lee C.L., So K.H., Gao J., Yeung W.S., Yao Y., et al. Soluble human leukocyte antigen-G5 activates extracellular signal-regulated protein kinase signaling and stimulates trophoblast invasion. PLoS One 2013, 8:e76023.
24. Chen B.G., Xu D.P., Lin A., Yan W.H. NK cytolysis is dependent on the proportion of HLA-G expression. Hum Immunol 2013, 74:286-289.
25. Baudhuin J., Lesport E., Sousa S., Migraine J., Vigneron J., Lemaoult J., et al. HLA-G inhibition of NK-cell cytolytic function is uncoupled from tumor cell lipid raft reorganization. Eur J Immunol 2012, 42:700-709.
26. Pistoia V., Morandi F., Wang X., Ferrone S. Soluble HLA-G: are they clinically relevant?. Semin Cancer Biol 2007, 17:469-479.
27. Morandi F., Ferretti E., Castriconi R., Dondero A., Petretto A., Bottino C., et al. Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood 2011, 118:5840-5850.
28. Bukur J., Rebmann V., Grosse-Wilde H., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003, 63:4107-4111.
29. Yan W.H., Lin A., Chen B.G., et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008, 12:889-898.
30. Murdaca G., Contini P., Setti M., Cagnati P., Spanò F., Lantieri F., et al. Soluble human leukocyte antigen-G serum levels in patients with acquired immune deficiency syndrome affected by different disease-defining conditions before and after antiretroviral treatment. Hum Immunol 2011, 72:712-716.
31. Murdaca G., Contini P., Setti M., Cagnati P., Lantieri F., Indiveri F., et al. Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. Clin Immunol 2009, 133:238-244.
32. Poláková K., Železníková T., Russ G. HLA-G5 in the blood of leukemia patients and healthy individuals. Leuk Res 2013, 37:139-145.
33. Li X.J., Zhang X., Lin A., Ruan Y.Y., Yan W.H. Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. Hum Immunol 2012, 73:946-949.
34. Carosella E.D., Gregori S., LeMaoult J. The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells. Blood 2011, 118:6499-6505.
35. Carosella E.D., Gregori S., Rouas-Freiss N., LeMaoult J., Menier C., Favier B. The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci 2011, 68:353-368.